Stockscreener 앱 받기
104.05
1.73%
1.925
전일 마감가:
$102.12
열려 있는:
$102.34
하루 거래량:
240.50K
Relative Volume:
0.43
시가총액:
$8.21B
수익:
-
순이익/손실:
$-425.38M
주가수익비율:
-17.78
EPS:
-5.8504
순현금흐름:
$-275.21M
1주 성능:
+2.86%
1개월 성능:
-0.59%
6개월 성능:
-4.75%
1년 성능:
+41.36%
1일 변동 폭
$101.86
$104.76
1주일 범위
$100.00
$104.76
52주 변동 폭
$70.25
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
명칭
Nuvalent Inc
전화
508-446-2272
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
103.87 | 8.07B | 0 | -425.38M | -275.21M | -5.8504 |
VRTX
Vertex Pharmaceuticals Inc
|
436.42 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.45 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.33 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.56 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.84 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-30 | 개시 | Wells Fargo | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-12 | 개시 | Canaccord Genuity | Buy |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-10-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-03-14 | 업그레이드 | UBS | Neutral → Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-10-24 | 개시 | UBS | Neutral |
| 2024-08-29 | 개시 | Barclays | Overweight |
| 2024-04-17 | 개시 | Jefferies | Buy |
| 2024-04-01 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 재개 | Guggenheim | Buy |
| 2024-02-23 | 개시 | Robert W. Baird | Outperform |
| 2023-09-27 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-24 | 개시 | Guggenheim | Buy |
| 2023-01-18 | 개시 | Wedbush | Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
모두보기
Nuvalent Inc 주식(NUVL)의 최신 뉴스
The Technical Signals Behind (NUVL) That Institutions Follow - Stock Traders Daily
Nuvalent, Inc. (NUVL) Stock Analysis: Evaluating a Potential 41.52% Upside in Biotech Innovation - DirectorsTalk Interviews
How Investors May Respond To Nuvalent (NUVL) NDA Filing And Early Zidesamtinib Response Data - Yahoo Finance
Bernstein initiates coverage of Nuvalent (NUVL) with outperform recommendation - MSN
Nuvalent’s SWOT analysis: biotech stock gains momentum on clinical data By Investing.com - Investing.com South Africa
Nuvalent’s SWOT analysis: biotech stock gains momentum on clinical data - Investing.com
NUVL Initiated Coverage by Bernstein -- Rating Set to Outperform - GuruFocus
Bernstein Initiates Nuvalent at Outperform - Moomoo
Nuvalent (NUVL) Receives Outperform Rating with $189 Target from Bernstein - GuruFocus
Bernstein initiates Nuvalent stock coverage with outperform rating By Investing.com - Investing.com Nigeria
Bernstein initiates Nuvalent stock coverage with outperform rating - Investing.com
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting - PR Newswire
Nuvalent ASCO 2026 Data Puts Neladalkib And Zidesamtinib In Focus - Sahm
Nuvalent Highlights Corporate and Pipeline Achievements and Repo - GuruFocus
CCORF Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $126 - Moomoo
Assessing Nuvalent (NUVL) Valuation After Recent Share Price Volatility And DCF Upside Signals - simplywall.st
Stifel Maintains Nuvalent (NUVL) Buy Recommendation - MSN
Precision Trading with Nuvalent Inc. (NUVL) Risk Zones - Stock Traders Daily
J.P. Morgan Maintains Nuvalent(NUVL.US) With Buy Rating, Cuts Target Price to $147 - Moomoo
TradingKey - TradingKey
H.C. Wainwright Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $155 - Moomoo
Nuvalent, Inc. (NUVL) Stock Analysis: 35% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
LifeSci Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $142 - Moomoo
Truist Financial Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Guggenheim Maintains Nuvalent(NUVL.US) With Buy Rating, Cuts Target Price to $151 - Moomoo
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $140 to $152 - Moomoo
Nuvalent: Buy Rating Reiterated on Strong Oncology Pipeline, Commercial Readiness, and Unchanged $142 Price Target - TipRanks
Nuvalent, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nuvalent Inc-A (NASDAQ:NUVL) Stock Edges Higher After Q1 2026 Earnings Miss as Investors Focus on Pipeline Milestones - ChartMill
Nuvalent (NUVL) widens Q1 loss as R&D spend rises and cash tops $1.3B - Stock Titan
Nuvalent (Nasdaq: NUVL) posts Q1 loss, advances dual lung cancer NDAs - Stock Titan
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results – Company AnnouncementFT.com - Financial Times
Nuvalent CEO James Porter sells $3.05m in NUVL shares, exercises options - Investing.com Canada
Nuvalent(NUVL.US) Officer Sells US$3.05 Million in Common Stock - Moomoo
Nuvalent (NUVL) CEO exercises options and sells 30,000 common shares - Stock Titan
Nuvalent earnings in focus as drug launch looms By Investing.com - Investing.com South Africa
Nuvalent earnings in focus as drug launch looms - Investing.com UK
FMR LLC reports 9.25M Nuvalent shares (12.6%) (NASDAQ: NUVL) - Stock Titan
Nuvalent CFO Balcom sells $1.13m in company stock By Investing.com - Investing.com South Africa
Nuvalent CFO Balcom sells $1.13m in company stock - Investing.com
Nuvalent (NUVL) CFO sells 11,430 shares, exercises options under plan - Stock Titan
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium - Quantisnow
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 43.75% Potential Upside with Promising Oncology Innovations - DirectorsTalk Interviews
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock - MarketBeat
Nuvalent Insider Sold Shares Worth $547,524, According to a Recent SEC Filing - marketscreener.com
Nuvalent Insider Sold Shares Worth $545,691, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CLO sells shares, exercises options in 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CDO nets 5,500-share sale after option exercise - Stock Titan
Canaccord Genuity Sticks to Their Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Nuvalent Inc (NUVL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Nuvalent Inc 주식 (NUVL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Porter James Richard | President and CEO |
May 04 '26 |
Sale |
101.69 |
30,000 |
3,050,712 |
324,879 |
| Balcom Alexandra | Chief Financial Officer |
May 01 '26 |
Option Exercise |
3.25 |
11,430 |
37,159 |
96,963 |
| Balcom Alexandra | Chief Financial Officer |
May 01 '26 |
Sale |
99.00 |
11,430 |
1,131,600 |
85,533 |
| Miller Deborah Ann | Chief Legal Officer |
Apr 30 '26 |
Option Exercise |
6.89 |
5,500 |
37,895 |
65,134 |
| Miller Deborah Ann | Chief Legal Officer |
Apr 30 '26 |
Sale |
99.22 |
5,500 |
545,691 |
59,634 |
| Noci Darlene | Chief Development Officer |
Apr 29 '26 |
Option Exercise |
27.85 |
5,500 |
153,175 |
63,617 |
| Noci Darlene | Chief Development Officer |
Apr 29 '26 |
Sale |
99.55 |
5,500 |
547,524 |
58,117 |
2.25%
0.46%
자본화:
|
볼륨(24시간):